Similar articles for PMID: 26030803

Year	Number of Results
2002	1
2003	1
2004	3
2005	1
2006	4
2007	6
2008	3
2009	6
2010	8
2011	10
2012	12
2013	19
2014	15
2015	12
2016	8
2017	5
2018	13
2019	10
2020	9
2021	7
2022	4
2023	1
2024	0

1

Computational Docking Study of p7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with Natural Compounds.

Mathew S, Fatima K, Fatmi MQ, Archunan G, Ilyas M, Begum N, Azhar E, Damanhouri G, Qadri I. Mathew S, et al. PLoS One. 2015 Jun 1;10(6):e0126510. doi: 10.1371/journal.pone.0126510. eCollection 2015. PLoS One. 2015. PMID: 26030803 Free PMC article.

2

Molecular design, synthesis and biological evaluation of cage compound-based inhibitors of hepatitis C virus p7 ion channels.

Shiryaev VA, Radchenko EV, Palyulin VA, Zefirov NS, Bormotov NI, Serova OA, Shishkina LN, Baimuratov MR, Bormasheva KM, Gruzd YA, Ivleva EA, Leonova MV, Lukashenko AV, Osipov DV, Osyanin VA, Reznikov AN, Shadrikova VA, Sibiryakova AE, Tkachenko IM, Klimochkin YN. Shiryaev VA, et al. Eur J Med Chem. 2018 Oct 5;158:214-235. doi: 10.1016/j.ejmech.2018.08.009. Epub 2018 Aug 6. Eur J Med Chem. 2018. PMID: 30218908

3

Understanding the inhibitory mechanism of BIT225 drug against p7 viroporin using computational study.

Behmard E, Abdolmaleki P, Taghdir M. Behmard E, et al. Biophys Chem. 2018 Feb;233:47-54. doi: 10.1016/j.bpc.2017.11.002. Epub 2017 Nov 16. Biophys Chem. 2018. PMID: 29169687

4

Computational Study of HCV p7 Channel: Insight into a New Strategy for HCV Inhibitor Design.

Ying B, Pang S, Yang J, Zhong Y, Wang J. Ying B, et al. Interdiscip Sci. 2019 Jun;11(2):292-299. doi: 10.1007/s12539-018-0306-3. Epub 2018 Sep 7. Interdiscip Sci. 2019. PMID: 30194627

5

"Too little, too late?" Will inhibitors of the hepatitis C virus p7 ion channel ever be used in the clinic?

Griffin S. Griffin S. Future Med Chem. 2014;6(17):1893-907. doi: 10.4155/fmc.14.121. Future Med Chem. 2014. PMID: 25495983

6

Structure-guided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release.

Foster TL, Thompson GS, Kalverda AP, Kankanala J, Bentham M, Wetherill LF, Thompson J, Barker AM, Clarke D, Noerenberg M, Pearson AR, Rowlands DJ, Homans SW, Harris M, Foster R, Griffin S. Foster TL, et al. Hepatology. 2014 Feb;59(2):408-22. doi: 10.1002/hep.26685. Epub 2013 Dec 24. Hepatology. 2014. PMID: 24022996 Free PMC article.

7

Inhibition of HCV p7 as a therapeutic target.

Griffin S. Griffin S. Curr Opin Investig Drugs. 2010 Feb;11(2):175-81. Curr Opin Investig Drugs. 2010. PMID: 20112167 Review.

8

Ion Channel Function and Cross-Species Determinants in Viral Assembly of Nonprimate Hepacivirus p7.

Walter S, Bollenbach A, Doerrbecker J, Pfaender S, Brown RJP, Vieyres G, Scott C, Foster R, Kumar A, Zitzmann N, Griffin S, Penin F, Pietschmann T, Steinmann E. Walter S, et al. J Virol. 2016 Apr 29;90(10):5075-5089. doi: 10.1128/JVI.00132-16. Print 2016 May 15. J Virol. 2016. PMID: 26962224 Free PMC article.

9

In depth analysis on the binding sites of adamantane derivatives in HCV (hepatitis C virus) p7 channel based on the NMR structure.

Du QS, Wang SQ, Chen D, Meng JZ, Huang RB. Du QS, et al. PLoS One. 2014 Apr 8;9(4):e93613. doi: 10.1371/journal.pone.0093613. eCollection 2014. PLoS One. 2014. PMID: 24714586 Free PMC article.

10

Investigation of viral escape mutations within HCV p7 during treatment with amantadine in patients with chronic hepatitis C.

Vermehren A, Welsch C, Elsler U, Vermehren J, Herrmann E, Sarrazin C, von Wagner M, Susser S, Hofmann WP, Kronenberger B, Zeuzem S, Mihm U. Vermehren A, et al. Antivir Ther. 2013;18(6):803-11. doi: 10.3851/IMP2663. Epub 2013 Jul 3. Antivir Ther. 2013. PMID: 23824381

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

139 results

Results by year